Country: Malta
Language: English
Source: Medicines Authority
MONTELUKAST
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
R03DC03
MONTELUKAST 10 mg
FILM-COATED TABLET
MONTELUKAST 10 mg
POM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Withdrawn
2005-06-30
Profile: 170 x 210 x 4 Profile Revision: G Profile Revision Date: 161008 Dimensions (mm): 170 x 210 Black Profile Technical Info Item No.: Revision Date & No.: Pharma Code: MBS Job No.: XXXXX XXXXXX-X XXX 350425 PACKAGE LEAFLET: INFORMATION FOR THE USER SINGULAIR® 10 MG FILM-COATED TABLETS montelukast READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have any further questions, please ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What SINGULAIR is and what it is used for 2. Before you take SINGULAIR 3. How to take SINGULAIR 4. Possible side effects 5. How to store SINGULAIR 6. Further information 1. WHAT SINGULAIR IS AND WHAT IT IS USED FOR SINGULAIR is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and swelling of airways in the lungs and also cause allergy symptoms. By blocking leukotrienes, SINGULAIR improves asthma symptoms, helps control asthma and improves seasonal allergy symptoms (also known as hay fever or seasonal allergic rhinitis). Your doctor has prescribed SINGULAIR to treat asthma, preventing your asthma symptoms during the day and night. • SINGULAIR is used for the treatment of patients who are not adequately controlled on their medication and need additional therapy. • SINGULAIR also helps prevent the narrowing of airways triggered by exercise. • In those asthmatic patients in whom SINGULAIR is indicated in asthma, SINGULAIR can also provide symptomatic relief of seasonal allergic rhinitis. Your doctor will determine how SINGULAIR should be used depending on the symptoms and severity of your asthma. WHAT IS ASTHMA? Asthma is a long-term disease. Asthma includ Read the complete document
1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT SINGULAIR 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains montelukast sodium, which is equivalent to 10 mg montelukast. _Excipient_: Lactose monohydrate 89.3 mg per tablet For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Beige, rounded square, film-coated, size 7.9 mm x 7.9 mm with SINGULAIR engraved on one side and MSD 117 on the other. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS SINGULAIR is indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting -agonists provide inadequate clinical control of asthma. In those asthmatic patients in whom SINGULAIR is indicated in asthma, SINGULAIR can also provide symptomatic relief of seasonal allergic rhinitis. SINGULAIR is also indicated in the prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstriction. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The dosage for adults and adolescents 15 years of age and older with asthma, or with asthma and concomitant seasonal allergic rhinitis, is one 10 mg tablet daily to be taken in the evening. _General recommendations_. The therapeutic effect of SINGULAIR on parameters of asthma control occurs within one day. SINGULAIR may be taken with or without food. Patients should be advised to continue taking SINGULAIR even if their asthma is under control, as well as during periods of worsening asthma. SINGULAIR should not be used concomitantly with other products containing the same active Read the complete document